Eloxx Pharmaceuticals, Inc. (ELOX) has 22 open-market insider trades by 11 insiders since 2018. The most active filer is Tomer Kariv, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Tomer Kariv | Dir | — | 4 | $24.7M | 2021-05-13 |
| Ran Nussbaum | Dir | — | 4 | $24.7M | 2021-05-13 |
| Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | — | 3 | $11.5M | 2021-05-13 |
| Rajesh B. Parekh | Dir | — | 1 | $6.7M | 2021-05-13 |
| Martijn Kleijwegt | Dir | — | 1 | $2.9M | 2018-04-30 |
| Gilad Shabtai | 10% Owner | — | 3 | $853K | 2018-04-30 |
| Robert Ward | CEO | — | 2 | $162K | 2020-02-29 |
| Pontifax IV GP L.P. | 10% | — | 1 | $98K | 2018-03-22 |
| Gregory L. Weaver | — | — | 1 | $39K | 2020-03-15 |
| Daniel E. Geffken | INTERIM CFO | — | 1 | $36K | 2021-11-29 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Daniel E. Geffken | INTERIM CFO | Buy | $36K | 2021-11-29 |
| Ran Nussbaum | Director | Buy | $16.0M | 2021-05-13 |
| Rajesh B. Parekh | Director | Buy | $6.7M | 2021-05-13 |
| Pontifax Management 4 G.P. (2015) Ltd. | 10% | Buy | $8.0M | 2021-05-13 |
| Ran Nussbaum | Director | Buy | $1.8M | 2019-06-24 |
| Robert Ward | CEO | Buy | $72K | 2018-05-22 |
Companies that share insiders with ELOX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Martijn Kleijwegt | Director | Buy | $2.9M | 2018-04-30 |
| Gilad Shabtai | 10% Owner | Buy | $731K | 2018-04-30 |
| Tomer Kariv | Director | Buy | $6.8M | 2018-04-30 |
| Pontifax Management 4 G.P. (2015) Ltd. | 10% | Buy | $3.4M | 2018-04-30 |
| Gilad Shabtai | 10% Owner | Buy | $79K | 2018-04-03 |
| Gilad Shabtai | 10% | Buy | $43K | 2018-03-29 |
| Zafrira Avnur | Director | Buy | $19K | 2018-03-26 |
| Gregory L. Weaver | CFO | Buy | $39K | 2018-03-23 |
| Robert Ward | CEO | Buy | $90K | 2018-03-23 |